Obesity, Type 2 Diabetes
Conditions
Interventions
None listed
Sponsors
Gubra A/S
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Outcome results
None listed
A three-part first-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GUB-UCN2 in healthy lean and obese participants and participants with T2D
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: May 12, 2026